

Göttingen, September 18, 2020

Sartorius awarded for its capital market communication

- Second place in the German MDAX index category of the Investors' Darling competition

Sartorius, a life science group, received an award for its capital market communication. The Göttingen-based company won second place in the MDAX index category in the Investors' Darling 2020 capital market competition. Overall, 160 of the largest German listed joint stock corporations were analyzed. The quality of their written and personal financial market communications was evaluated for the rankings in various categories. Sartorius has received an Investors' Darling award four times already. "We attach great importance to transparent and understandable communication with all our stakeholders. The competition serves as a gauge of how our exchange of information with the capital market is perceived. We appreciate the feedback from outside, as well as the detailed benchmarking because it provides us with points of approach for us to enhance our interaction even further," commented Petra Kirchhoff, Head of Corporate Communications and Investor Relations at Sartorius.

The HHL Leipzig Graduate School of Management and the German business journal *Manager Magazin* have been holding the competition annually since 2014 to assess the quality of the financial communication of German joint stock corporations. The Investors' Darling evaluation is considered the most comprehensive analysis of capital market communication in Germany.

A profile of Sartorius

The Sartorius Group is a leading international partner of life science research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group's Lab Products & Services Division concentrates on serving the needs of laboratories performing research and quality control at pharma and biopharma companies and those of academic research institutes. The Bioprocess Solutions Division with its broad product portfolio focusing on single-use solutions helps customers to manufacture biotech medications and vaccines safely and efficiently. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In fiscal 2019, the company earned sales revenue of some 1.83 billion euros. At the end of 2019, more than 9,000 people were employed at the Group's approximately 60 manufacturing and sales sites, serving customers around the globe.

Contact

Timo Lindemann

Corporate Communications

+49 (0)551.308.4724

timo.lindemann@sartorius.com

sartorius.com

Follow Sartorius on [Twitter @Sartorius_Group](#) and on [LinkedIn](#).